Table 1. Zolbetuximab post-infusion monitoring periods1
Infusion | Clinical circumstance | Post-infusion monitoring perioda |
|---|---|---|
First infusion | All patients | At least two hours after completion |
Subsequent infusions | Grade ≥ 2 AEs observed during the first infusion or post-infusion monitoring period | Approximately two hours after completion |
Subsequent infusions | No Grade ≥ 2 AEs during the first infusion or post-infusion monitoring period | At least one hour after completion |
AE: adverse event
aThe post-infusion monitoring period may be extended if clinically indicated, based on physician clinical judgment.
Data on File.
Shitara K, Lordick F, Bang YJ, et al. Supplement to: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. Available at: https://doi.org/10.1016/s0140-6736(23)00620-7.
Shah MA, Shitara K, Ajani JA, et al. Supplement to: Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 2023;29(8):2133-2141. Available at: https://doi.org/10.1038/s41591-023-02465-7.
If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here